Germline BRCA1/2 Mutations and p27Kip1 Protein Levels Independently Predict Outcome After Breast Cancer
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
PURPOSE: Decreased levels of the cyclin-dependent kinase inhibitor p27 Kip1 in breast cancer are associated with a poor outcome. The prognostic significance of BRCA1/2 mutations is less clear, and the relationship between BRCA1/2 mutation status, p27 Kip1 protein levels, and outcome has not been studied. PATIENTS AND METHODS: Pathology blocks from 202 consecutive Ashkenazi Jewish women with primary invasive breast cancer were studied. Tumor DNA was tested for the three common BRCA1/2 founder mutations present in Ashkenazi Jews, and p27 Kip1 expression was evaluated by immunohistochemistry. The median follow-up was 6.4 years. RESULTS: Thirty-two tumors (16%) were positive for a BRCA1/2 mutation. Low p27 Kip1 expression was seen in 110 tumors (63%) and was significantly associated with BRCA1/2 mutations (odds ratio, 4.0; 95% confidence interval [CI], 1.4 to 11.1; P = .009). BRCA1/2 mutation carriers had a significantly worse 5-year distant disease-free survival (DDFS) compared with women without BRCA1/2 mutations (58% v 82%; P = .003). Similar results were seen for women whose tumors expressed low levels of p27 Kip1, compared with those with high levels (5-year DDFS, 68% v 93%; P < .0001). In a multivariate analysis, both BRCA1/2 mutation and low p27 Kip1 expression were associated with a shorter DDFS (relative risk [RR], 2.1; 95% CI, 1.0 to 4.3; P = .05; and RR, 3.9; 95% CI, 1.4 to 11.1; P = .01, respectively). CONCLUSION: In this study, we showed that BRCA1/2 mutations were associated with low levels of p27 Kip1 in breast cancer. Both BRCA1/2 and p27 Kip1 status were identified as independent prognostic factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Survival and tumor characteristics of German hereditary breast cancer patients
Hamann, U., & Sinn, H.-P. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006350518190 · Cited by 48
Prognosis and clinical presentation of BRCA2-associated breast cancer
Loman, N., Johannsson, O., Bendahl, P.-O., Dahl, N., Einbeigi, Z., Gerdes, A.-M., Borg, Å., & Olsson, H. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00098-8 · Cited by 46
Research works printed but not linked: 35
- 10.1056/NEJM199206253262607 · DOI · Paper page
- 10.3322/canjclin.47.1.28 · DOI · Paper page
- 10.1093/jnci/90.21.1601 · DOI · Paper page
- 10.1146/annurev.med.50.1.401 · DOI · Paper page
- 10.1038/18105 · doi:10.1038/18105
- 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I · DOI · Paper page
- 10.1023/A:1006154900130 · DOI
- 10.1038/nm0297-222 · DOI · Paper page
- 10.1038/nm0297-227 · DOI · Paper page
- 10.1002/(SICI)1096-9098(199904)70:4<230::AID-JSO6>3.0.CO;2-I · doi:10.1002/(sici)1096-9098(199904)70:4<230::aid-jso6>3.0.co;2-i
- 10.1038/sj.bjc.6690250 · DOI
- 10.1016/S0304-3835(99)00084-1 · doi:10.1016/s0304-3835(99)00084-1
- 10.1200/JCO.1998.16.5.1969 · DOI · Paper page
- 10.1016/S0140-6736(96)10109-4 · DOI · Paper page
- 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W · DOI · Paper page
- 10.1093/jnci/90.15.1138 · DOI · Paper page
- 10.1038/sj.onc.1202106 · DOI · Paper page
- 10.1023/A:1008301314812 · DOI
- 10.1200/JCO.1999.17.11.3653 · DOI · Paper page
- 10.1093/jnci/91.24.2112 · DOI · Paper page
- 10.1007/BF01805951 · doi:10.1007/bf01805951
- 10.1200/JCO.1999.17.11.3396 · DOI · Paper page
- Tonin P, Weber B, Offit K, et al: Frequency of recurrent and mutations in Ashkenazi Jewish breast cancer families. Nat Med 2: 1183,1996-1196, BRCA1 BRCA2 · DOI · Paper page
- 10.1038/ng1096-185 · DOI · Paper page
- 10.1093/jnci/91.14.1241 · DOI · Paper page
- 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y · doi:10.1002/(sici)1097-0142(19970801)80:3<435::aid-cncr11>3.0.co;2-y
- 10.1002/(SICI)1096-9896(199901)187:2<200::AID-PATH228>3.0.CO;2-M · DOI
- 10.1016/S0140-6736(05)79248-5 · DOI
- 10.1200/JCO.2000.18.24.4053 · DOI · Paper page
- 10.1038/38291 · DOI · Paper page
- Han S, Park K, Kim HY, et al: Reduced expression of p27 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation. Breast Cancer Res Treat 55: 161,1999-167, Kip1 · doi:10.1023/a:1006258222233
- 10.1038/8743 · DOI · Paper page
- 10.1038/387422a0 · DOI · Paper page
- 10.1038/24179 · DOI · Paper page
- 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H · DOI · Paper page
Cited by
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
Chu, I. M., Hengst, L., & Slingerland, J. M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2347 · Cited by 990
Self-citationRe: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
Contralateral Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., Olopade, O. I., Eisen, A., Weber, B., McLennan, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.033 · Cited by 621
Self-citationTriple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes
Rakha, E. A., Elsheikh, S. E., Aleskandarany, M. A., Habashi, H. O., Green, A. R., Powe, D. G., El-Sayed, M. E., Benhasouna, A., Brunet, J.-S., Akslen, L. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2132 · Cited by 489
Self-citationFoulkes, W. D., Brunet, J.-S., Stefansson, I. M., Straume, O., Chappuis, P. O., Bégin, L. R., Hamel, N., Goffin, J. R., Wong, N., Trudel, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2970 · Cited by 363
Self-citation
Metadata
- Authors
- Chappuis, P. O., Kapusta, L., Bégin, L. R., Wong, N., Brunet, J.-S., Narod, S. A., Slingerland, J., & Foulkes, W. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-12-15
- Volume
- 18
- Issue
- 24
- Pages
- 4045-4052
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2258788178
- Cited by
- 119
- References
- 3
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Germline BRCA1/2 Mutations and p27Kip1 Protein Levels Independently Predict Outcome After Breast Cancer. https://app.cochat.ai/papers/10.1200/jco.2000.18.24.4045
- The paper
- Chappuis, P. O., Kapusta, L., Bégin, L. R., Wong, N., Brunet, J.-S., Narod, S. A., Slingerland, J., & Foulkes, W. D. (2000). Germline BRCA1/2 Mutations and p27Kip1 Protein Levels Independently Predict Outcome After Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2000.18.24.4045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.